This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Labrosse, B. Articles by Alizon, M. Search for Related Content PubMed PubMed Citation Articles by Labrosse, B. Articles by Alizon, M.

 Previous Article  |  Next Article 

J. Virol., 11 1997, 8230-8236, Vol 71, No. 11
Copyright © 1997, American Society for Microbiology

Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41

B Labrosse, O Pleskoff, N Sol, C Jones, Y Henin and M Alizon
INSERM, Institut Cochin de Genetique Moleculaire, Paris, France.

A triterpene derived from betulinic acid (RPR103611) blocks human immunodeficiency virus type 1 (HIV-1) infection and fusion of CD4+ cells with cells expressing HIV-1 envelope proteins (gp120 and gp41), suggesting an effect on virus entry. This compound did not block infection by a subtype D HIV-1 strain (NDK) or cell-cell fusion mediated by the NDK envelope proteins. The genetic basis of drug resistance was therefore addressed by testing envelope chimeras derived from NDK and a drug-sensitive HIV-1 strain (LAI, subtype B). A drug- resistant phenotype was observed for all chimeras bearing the ectodomain of NDK gp41, while the origins of gp120 and of the membrane anchor and cytoplasmic domains of gp41 had no apparent role. The envelope gene of a LAI variant, fully resistant to the antiviral effect of RPR103611, was cloned and sequenced. Its product differed from the parental sequence at two positions in gp41, with changes of arginine 22 to alanine (R22A) and isoleucine 84 to serine (I84S), the gp120 being identical. In the context of LAI gp41, the I84S substitution was sufficient for drug resistance. Therefore, in two different systems, differences in gp41 were associated with sensitivity or resistance to RPR103611. Modifications of gp41 can affect the quaternary structure of gp120 and gp41 and the accessibility of gp120 to antiviral agents such as neutralizing antibodies. However, a direct effect of RPR103611 on a gp41 target must also be envisioned, in agreement with the blocking of apparently late steps of HIV-1 entry. This compound could be a valuable tool for structure-function studies of gp41.

This article has been cited by other articles:

• Jin, B.-S., Lee, W.-K., Ahn, K., Lee, M. K., Yu, Y. G. (2005). High-Throughput Screening Method of Inhibitors that Block the Interaction between 2 Helical Regions of HIV-1 gp41. J Biomol Screen 10: 13-19 [Abstract]  
• Bonnenfant, S., Thomas, C. M., Vita, C., Subra, F., Deprez, E., Zouhiri, F., Desmaele, D., d'Angelo, J., Mouscadet, J. F., Leh, H. (2004). Styrylquinolines, Integrase Inhibitors Acting Prior to Integration: a New Mechanism of Action for Anti-Integrase Agents. J. Virol. 78: 5728-5736 [Abstract] [Full Text]  
• Bar, S., Alizon, M. (2004). Role of the Ectodomain of the gp41 Transmembrane Envelope Protein of Human Immunodeficiency Virus Type 1 in Late Steps of the Membrane Fusion Process. J. Virol. 78: 811-820 [Abstract] [Full Text]  
• Labrosse, B., Treboute, C., Brelot, A., Alizon, M. (2001). Cooperation of the V1/V2 and V3 Domains of Human Immunodeficiency Virus Type 1 gp120 for Interaction with the CXCR4 Receptor. J. Virol. 75: 5457-5464 [Abstract] [Full Text]  
• Holz-Smith, S. L., Sun, I-C., Jin, L., Matthews, T. J., Lee, K.-H., Chen, C. H. (2001). Role of Human Immunodeficiency Virus (HIV) Type 1 Envelope in the Anti-HIV Activity of the Betulinic Acid Derivative IC9564. Antimicrob. Agents Chemother. 45: 60-66 [Abstract] [Full Text]  
• Labrosse, B., Treboute, C., Alizon, M. (2000). Sensitivity to a Nonpeptidic Compound (RPR103611) Blocking Human Immunodeficiency Virus Type 1 Env-Mediated Fusion Depends on Sequence and Accessibility of the gp41 Loop Region. J. Virol. 74: 2142-2150 [Abstract] [Full Text]  
• Kurokawa, M., Basnet, P., Ohsugi, M., Hozumi, T., Kadota, S., Namba, T., Kawana, T., Shiraki, K. (1999). Anti-Herpes Simplex Virus Activity of Moronic Acid Purified from Rhus javanica In Vitro and In Vivo. J. Pharmacol. Exp. Ther. 289: 72-78 [Abstract] [Full Text]  
• Labrosse, B., Brelot, A., Heveker, N., Sol, N., Schols, D., De Clercq, E., Alizon, M. (1998). Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100. J. Virol. 72: 6381-6388 [Abstract] [Full Text]